Y Wu, L Zhou, Y Zou, Y Zhang, M Zhang, L Xu, L Zheng… - Nature cancer, 2023 - nature.com
Immunotherapies targeting the PD-1/PD-L1 axis have become first-line treatments in
multiple cancers. However, only a limited subset of individuals achieves durable benefits …